A retrospective study comparing prognostic performance of Chemotherapy rechallenge or reintroduction, Regorafenib (REG) and TAS-102 for metastatic pretreated colorectal cancer patients
Latest Information Update: 23 Dec 2019
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary) ; Antineoplastics
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PROSERpINA Study
Most Recent Events
- 08 Jun 2019 New trial record
- 04 Jun 2019 Results of retrospective comparison of treatments with chemotherapy rechallenge or reintroduction, Regorafenib (REG) and TAS-102 presented at the 55th Annual Meeting of the American Society of Clinical Oncology.